Cite

HARVARD Citation

    Chiappori, A. et al. (2016). A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist. pp. 1163-1164e. [Online]. 
  
Back to record